Active Recombinant Human CD70 protein, Fc-tagged, R-PE labeled

• Cat.No.: CD70-639P
• Product Overview: Recombinant Human CD70 protein, Fc-tagged was Conjugated with NH2-Reactive R-PE(R-Phycoerythrin).

Specification

• Source: HEK293
• Species: Human
• Tag: Fc
• Form: Lyophilized from sterile 50 mM Tris, pH 8.0.
  Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Bio-activity: Measured by its binding ability in a functional ELISA. Immobilized Human CD27 His at 2 μg/ml (100 μl/well) can bind Human CD70 hFc, the EC50 of Human CD70 hFc is 15-60 ng/mL.
• Molecular Mass: The recombinant human CD70/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 413 amino acids and predicts a molecular mass of 45.5 kDa. As a result of different glycosylation, the rh CD70/Fc migrates as several bands with the approximate molecular mass of 55-60, 110-120 and 160-170 kDa corresponding to the monomeric, dimeric and trimeric form respectively in SDS-PAGE under reducing conditions.
• Protein Length: Gln 39-Pro 193
• Endotoxin: < 1.0 EU per μg protein as determined by the LAL method.
• Purity: > 90 % as determined by SDS-PAGE.
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C
  Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.

Gene Information

• Gene Name: CD70 CD70 molecule [ Homo sapiens ]
• Official Symbol: CD70
• Synonyms: CD70; CD70 molecule; CD27LG, TNFSF7, tumor necrosis factor (ligand) superfamily, member 7; CD70 antigen; CD27L; CD27-L; CD27 ligand; Ki-24 antigen; surface antigen CD70; tumor necrosis factor ligand superfamily member 7; tumor necrosis factor (ligand) superfamily, member 7; CD27LG; TNFSF7
• Gene ID: 970
• mRNA Refseq: NM_001252
• Protein Refseq: NP_001243
• MIM: 602840
• UniProt ID: P32970

Reviews

05/31/2021

Their collaboration, expertise, and customized solutions contribute to the successful execution of experiments, reliable data generation, and the advancement of scientific knowledge in the field.

04/23/2019

the manufacturer's support is crucial for researchers using CD70 protein in trials.

03/07/2017

These resources can enhance the efficiency and accuracy of experimental workflows and contribute to successful outcomes.

Q&As

What are some potential CD70-targeted therapies for cancer?

Antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T-cell therapies are being developed to target CD70 in cancer.

How can CD70-targeted therapies improve cancer treatment outcomes?

CD70-targeted therapies can enhance the body's immune response against cancer cells and potentially lead to more effective treatments.

In which hematological malignancies is CD70 expression frequently observed?

CD70 expression is often observed in Hodgkin's lymphoma and certain types of T-cell lymphomas.

Are there any challenges in developing CD70-targeted therapies for cancer?

Challenges include potential toxicities and finding the right balance to target CD70 effectively without harming normal immune functions.

Are there clinical trials involving CD70-targeted therapies for cancer treatment?

Yes, there are ongoing clinical trials exploring CD70-targeted therapies for various cancer types.